Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 4/20 | 0.66 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | JAK1 | P23458 | 1/20 | 0.58 |
| ▸ | TYK2 | P29597 | 1/20 | 0.58 |
| ▸ | JAK3 | P52333 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | GSK3A | P49840 | 3/20 | 0.55 |
| ▸ | GSK3B | P49841 | 3/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4047768 | 0.85 | FLT3 (0.64) | FLT3LMNASMN1; SMN2JAK2JAK3 | |
| SCHEMBL4047489 | 0.85 | FLT3 (0.74) | FLT3LMNASMN1; SMN2JAK2JAK1 | |
| SCHEMBL4040002 | 0.85 | FLT3 (0.67) | FLT3LMNASMN1; SMN2JAK2JAK1 | |
| SCHEMBL2088682 | 0.84 | FLT3 (0.75) | FLT3JAK2JAK1TYK2JAK3 | |
| SCHEMBL23000583 | 0.81 | MAPK1 (0.70) | FLT3LMNASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL12780847 | 0.80 | BACE1 (0.58) | FLT3SMN1; SMN2JAK2JAK1TYK2 | |
| SCHEMBL12779220 | 0.80 | FLT3 (1.00) | FLT3SMN1; SMN2JAK2CA12CA1 | |
| SCHEMBL4039312 | 0.80 | FLT3 (0.62) | FLT3LMNASMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL2088175 | 0.79 | FLT3 (0.63) | FLT3LMNASMN1; SMN2JAK2JAK1 | |
| SCHEMBL12779226 | 0.78 | FLT3 (0.60) | FLT3LMNASMN1; SMN2JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| EP-1562589-B1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K5 | FLT3 220/4885LMNA 3537/4885SMN1; SMN2 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.